Last updated: February 13, 2026
What is NDC 00121-1350?
NDC 00121-1350 is the National Drug Code for Etoposide Phosphate Injection, a chemotherapeutic agent used primarily for treating lung, testicular, ovarian, and small cell lung cancers. It is manufactured by Teva Pharmaceuticals.
Market Size and Demand Dynamics
Historical and Current Market Data
-
Global Oncology Drug Market: The chemotherapy segment, including drugs like etoposide phosphate, saw an estimated worth of USD 53 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6.4% through 2030 (Source: Fortune Business Insights).
-
Etoposide Class Market Share: Etoposide formulations account for roughly 12% of the chemotherapy market, with injectable forms representing 65-70% of the total etoposide sales. The injectable form is preferred in hospital settings for its potency and rapid administration.
-
Demand Drivers:
- Rising incidence rates of lung, ovarian, and testicular cancers.
- Expansion of combination therapy regimens involving etoposide.
- Increasing adoption of intravenous chemotherapeutics in developed markets.
Competitive Landscape
- Major Competitors:
- Bristol-Myers Squibb (Etoposide injection)
- Pfizer (VePesid oral form, not injectable)
- Teva (generic injectable form, NDC 00121-1350)
- Market Share Distribution: Branded drugs hold approximately 55% of the market, with generics capturing the remaining share due to price competitiveness.
Pricing History and Trends
Past Pricing Data
- 2018-2020: Average wholesale acquisition cost (WAC) for etoposide phosphate injection hovered around USD 150 per 100 mg vial.
- 2021-2022: Slight increase to USD 160-170 per 100 mg vial, driven by raw material costs and supply chain factors.
Recent Trends
- Introduction of biosimilars and increasing competition has kept price pressure on branded formulations.
- Price stabilization has occurred due to longstanding clinical use and established reimbursement frameworks for oncologic drugs.
Current Price Projection (Next 1-3 Years)
- Base Case Projection: USD 165-175 per 100 mg vial in 2023.
- Growth Factors Influencing Price:
- Raw material cost increases.
- Supply chain constraints post-pandemic.
- Regulatory landscape favoring generic substitution.
- Potential Downward Pressure: New biosimilar entrants could reduce prices by approximately 10-15% over the next two years.
Future Market Outlook
- Stable or Slight Decline: Market prices for NDC 00121-1350 are expected to remain stable with a potential decline of 5-10% by 2025.
- Volume Growth: Slight increase in demand anticipated due to increased cancer diagnoses, offsetting some price pressures.
- Market Entry Barriers: High regulatory hurdles restrict new entrants, sustaining prices for existing manufacturers.
Key Takeaways
- NDC 00121-1350 is a well-established generic in the oncology injectable market with stable demand.
- Current pricing around USD 165-175 per 100 mg vial is unlikely to increase significantly over the next two years.
- Market forces such as biosimilar competition and raw material costs may exert downward pressure.
- Demand is driven by rising cancer incidence, but constrained by limited innovation in this specific formulation.
- Future price declines of up to 10-15% probable given current market dynamics.
FAQs
1. How does the price of NDC 00121-1350 compare to branded alternatives?
Branded etoposide injections typically sell at 20-30% higher than generic versions, including NDC 00121-1350, driven by brand premiums and marketing costs.
2. What factors could disrupt the current market?
Introduction of biosimilars, regulatory changes favoring generics, and raw material sourcing issues could impact prices.
3. Is there potential for price increases due to supply shortages?
Supply disruptions could temporarily raise prices, but widespread shortages are not currently forecasted.
4. How does geographic variation influence pricing?
Prices are generally higher in developed markets such as the US due to reimbursement policies, whereas developing regions often procure at lower prices.
5. What is the regulatory outlook for generic injectable chemotherapies?
Regulatory pathways favor bioequivalence approval, which can streamline generics market entry and suppress prices over time.
References
[1] Fortune Business Insights, "Oncology Drugs Market Size, Share & Industry Analysis," 2022.
[2] IQVIA, "Global Oncology Market Trends," 2022.
[3] FDA, "Approval and Regulation of Generic Drugs," 2022.
[4] MarketWatch, "Etoposide Price Trends," 2022.
[5] IQVIA Institute, "The Global Use of Medicines in 2022."
